{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:23:56Z","timestamp":1778768636289,"version":"3.51.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ekir.2019.08.005","type":"journal-article","created":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T12:11:15Z","timestamp":1566303075000},"page":"1366-1372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Individualizing Therapy in Lupus Nephritis"],"prefix":"10.1016","volume":"4","author":[{"given":"Yu","family":"An","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4592-7494","authenticated-orcid":false,"given":"Zhihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2019.08.005_bib1","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3899\/jrheum.180145","article-title":"Improvement of outcomes in patients with lupus nephritis: management evolution in Chinese patients from 1994 to 2010","volume":"46","author":"Shao","year":"2019","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.ekir.2019.08.005_bib2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/art.40729","article-title":"All-cause and cause-specific mortality trends of end-stage renal disease due to lupus nephritis from 1995 to 2014","volume":"71","author":"Jorge","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ekir.2019.08.005_bib3","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1681\/ASN.2016040415","article-title":"Current and emerging therapies for lupus nephritis","volume":"27","author":"Parikh","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.08.005_bib4","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971\u20132015:a systematic review and bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ekir.2019.08.005_bib5","doi-asserted-by":"crossref","first-page":"e794","DOI":"10.1097\/MD.0000000000000794","article-title":"Long-term survival and death causes of systemic lupus erythematosus in China: a systemic review of observational studies","volume":"94","author":"Wang","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ekir.2019.08.005_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10067-018-4259-z","article-title":"Causes of death in hospitalized patients with systemic lupus erythematosus: a 10-year multicenter nationwide Chinese cohort","volume":"38","author":"Wu","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ekir.2019.08.005_bib7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/1574887112666171123113200","article-title":"Lupus nephritis: current treatment paradigm and unmet needs","volume":"13","author":"Menez","year":"2018","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.ekir.2019.08.005_bib8","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrneph.2017.85","article-title":"Redefining lupus nephritis: clinical implications of pathophysiologic subtypes","volume":"13","author":"Yu","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2019.08.005_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrrheum.2012.208","article-title":"Global trends, potential mechanisms and early detection of organ damage in SLE","volume":"9","author":"Mak","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ekir.2019.08.005_bib10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0140-6736(04)16808-6","article-title":"Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial","volume":"364","author":"Remuzzi","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2019.08.005_bib11","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.08.005_bib12","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/ndt\/gfv102","article-title":"Lupus nephritis management guidelines compared","volume":"31","author":"Wilhelmus","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.08.005_bib13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.kint.2018.11.008","article-title":"Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.08.005_bib14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.berh.2017.09.010","article-title":"Calcineurin inhibitors in systemic lupus erythematosus","volume":"31","author":"Mok","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.ekir.2019.08.005_bib15","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2019.08.005_bib16","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/ndt\/gfp778","article-title":"Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study","volume":"25","author":"Ekberg","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.08.005_bib17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/TP.0b013e31821fad06","article-title":"Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation","volume":"92","author":"Ekberg","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2019.08.005_bib18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1053\/j.ajkd.2010.08.036","article-title":"Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial","volume":"57","author":"Chen","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2019.08.005_bib19","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1681\/ASN.2007121272","article-title":"Successful treatment of class V+IV lupus nephritis with multitarget therapy","volume":"19","author":"Bao","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.08.005_bib20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2019.08.005_bib21","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.kint.2017.08.031","article-title":"Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis","volume":"93","author":"Fu","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.08.005_bib22","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.ajkd.2016.12.008","article-title":"Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials","volume":"70","author":"Palmer","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2019.08.005_bib23","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/ndt\/gfu184","article-title":"To TDM or not to TDM in lupus nephritis patients treated with MMF?","volume":"30","author":"van Gelder","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.08.005_bib24","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1681\/ASN.2017030263","article-title":"Multitarget therapy for maintenance treatment of lupus nephritis","volume":"28","author":"Zhang","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.08.005_bib25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41584-018-0133-2","article-title":"New therapeutic strategies in systemic lupus erythematosus management","volume":"15","author":"Gatto","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ekir.2019.08.005_bib26","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/0961203310366572","article-title":"Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus","volume":"19","author":"Nossent","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2019.08.005_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.09.004","article-title":"Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study","volume":"86","author":"Iaccarino","year":"2018","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.ekir.2019.08.005_bib28","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1177\/0961203318758505","article-title":"Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis","volume":"27","author":"Choi","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2019.08.005_bib29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijpam.2018.08.001","article-title":"Combination of tacrolimus and mycophenolate mofetil in persistent proteinuria due to refractory childhood lupus nephritis","volume":"5","author":"Almutairi","year":"2018","journal-title":"Int J Pediatr Adolesc Med"},{"key":"10.1016\/j.ekir.2019.08.005_bib30","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1177\/0961203318758508","article-title":"Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis","volume":"27","author":"Jesus","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2019.08.005_bib31","first-page":"105","article-title":"Addition of cyclosporine\/tacrolimus for pediatric relapsed lupus nephritis during mycophenolate mofetil maintenance therapy","volume":"47","author":"Mao","year":"2019","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.ekir.2019.08.005_bib32","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/1756-185X.13321","article-title":"Induction therapy for membranous lupus nephritis: a systematic review and\u00a0network meta-analysis","volume":"21","author":"Tang","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ekir.2019.08.005_bib33","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3906\/sag-1804-57","article-title":"Multitarget therapy versus intravenous cyclophosphamide in the induction treatment of lupus nephritis: a metaanalysis of randomized controlled trials","volume":"48","author":"Deng","year":"2018","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.ekir.2019.08.005_bib34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A\u00a0randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.08.005_bib35","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1080\/14656566.2018.1516751","article-title":"An evaluation of voclosporin for the treatment of lupus nephritis","volume":"19","author":"Sin","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ekir.2019.08.005_bib36","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1177\/0961203314528553","article-title":"Efficacy of mizoribine-tacrolimus-based induction therapy for pediatric lupus nephritis","volume":"23","author":"Tanaka","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2019.08.005_bib37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/0961203317719148","article-title":"Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan","volume":"27","author":"Sakai","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2019.08.005_bib38","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s10157-018-1597-8","article-title":"The first year results of mizoribine\/tacrolimus-based multitarget treatment for consecutive patients with lupus nephritis","volume":"22","author":"Kagawa","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2019.08.005_bib39","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11926-018-0766-9","article-title":"Induction therapy for lupus nephritis: the highlights","volume":"20","author":"Ayoub","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.ekir.2019.08.005_bib40","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/rheumatology\/keu369","article-title":"Belimumab after rituximab as maintenance therapy in lupus nephritis","volume":"53","author":"Kraaij","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2019.08.005_bib41","first-page":"355","article-title":"Rituximab-refractory lupus nephritis successfully treated with belimumab","volume":"34","author":"Gonzalez-Echavarri","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ekir.2019.08.005_bib42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jbspin.2016.01.008","article-title":"Successful treatment of refractory lupus nephritis by the sequential use\u00a0of rituximab and belimumab","volume":"84","author":"Simonetta","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ekir.2019.08.005_bib43","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/0961203317717084","article-title":"Successful use of sequential B-cell depletion therapy in lupus","volume":"27","author":"Psarelis","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2019.08.005_bib44","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12882-018-1066-3","article-title":"Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report","volume":"19","author":"Fontana","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2019.08.005_bib45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaut.2018.03.003","article-title":"The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus","volume":"91","author":"Kraaij","year":"2018","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.ekir.2019.08.005_bib46","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","article-title":"Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus","volume":"49","author":"Jenks","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.ekir.2019.08.005_bib47","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1084\/jem.20122798","article-title":"Overexpression of TLR7\u00a0promotes cell-intrinsic expansion and autoantibody production by transitional T1 B cells","volume":"210","author":"Giltiay","year":"2013","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.ekir.2019.08.005_bib48","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1084\/jem.20150585","article-title":"Altered BCR and TLR signals promote enhanced positive selection of autoreactive transitional B cells in Wiskott-Aldrich syndrome","volume":"212","author":"Kolhatkar","year":"2015","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.ekir.2019.08.005_bib49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1681\/ASN.2005070714","article-title":"Toll-like receptor-7 modulates immune complex glomerulonephritis","volume":"17","author":"Pawar","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.08.005_bib50","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.clim.2016.07.015","article-title":"Toll-like receptor activation in the pathogenesis of lupus nephritis","volume":"185","author":"Lorenz","year":"2017","journal-title":"Clin Immunol"},{"issue":"Suppl 3","key":"10.1016\/j.ekir.2019.08.005_bib51","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1186\/ar565","article-title":"The paradigm of IL-6: from basic science to medicine","volume":"4","author":"Naka","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1016\/j.ekir.2019.08.005_bib52","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1191\/0961203304lu1023oa","article-title":"Rationale for interleukin-6 blockade in systemic lupus erythematosus","volume":"13","author":"Tackey","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2019.08.005_bib53","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/art.39722","article-title":"A\u00a0multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis","volume":"68","author":"Rovin","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ekir.2019.08.005_bib54","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/annrheumdis-2016-209668","article-title":"Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial","volume":"76","author":"Wallace","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024919314615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024919314615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:25:46Z","timestamp":1762831546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024919314615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S2468024919314615"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2019.08.005","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualizing Therapy in Lupus Nephritis","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2019.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}